Human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can provide a promising source of midbrain dopaminergic (DA) neurons for cell replacement therapy for Parkinson's disease (PD). To evaluate safety and efficacy of the human ESC-derived DA neurons, we induced neural progenitor cells from human ESCs by a modified SDIA (stromal cell-derived inducing activity) method. When the cells were transplanted into the bilateral striatum of monkey models of PD, they did not form tumors and survived as DA neurons as long as 12 months proved by immunofluorescence and PET studies. In addition, the monkeys showed behavioral improvement after 3 months post-transplantation. We also generated DA neurons from human induced pluripotent stem cells (iPSCs) without feeder cells, and confirmed that these cells could survive as long as 6 months in the monkey brain. These results support the idea that human ESCs/iPSCs can be used as a source for cell replacement therapy of PD. However, ESC/iPSC-derived donor cells may inevitably contain tumorigenic or inappropriate cells. Therefore, as a next step, we have developed a method for 1) scalable DA neuron induction on human laminin fragment and 2) sorting DA progenitor cells using a floor plate marker. The sorting of DA progenitor cells is favorable in terms of both safety and efficacy of the transplantation, and we have now established a protocol for the clinical application of human iPSCs to treat Parkinson's disease.
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The term of 'humanized mouse' model have recently become popular since in the early 2000s, a series of immunodeficient mice such as NOG, NSG and BRG mice appropriate for generating humanized mice has been successively developed. These strains show not only a high rate of human cell engraftment but also generate well-differentiated multi-lineage human hematopoietic cells after human hematopoietic stem cell (HSC) transplantation. Humanize mouse models are extremely useful for the study of mechanisms underlying various human disease and in drug development. Various human disease mouse models using these humanized mice have been actually developed. However, human hematopoietic cells developed from HSCs are not always phenotypically and functionally identical to those in humans. To overcome these disadvantages, development of a new series of immunodeficient mice has been attempted by genetically introducing human cytokine genes into NOG mice. Our institute, CIEA has a long history for development of immunodeficient mice. The history started from 1973 when Dr. Tatsuji Nomura, the late director of CIEA, introduced nude mice from Dr. Friis of Denmark. In this presentation, I will talk on the history to NOG mice, and the resulting NOG and the further improved immunodeficient mice and their application as humanized models, and also discuss on what strategies to pursue more appropriate humanized mouse models. Finally, I sincerely express my gratitude to Dr. Nomura for his forethought, enthusiasm and guide on these studies.
